SAB Biotherapeutics Inc Cash Flow-to-Debt Ratio
SAB Biotherapeutics Inc cash flow-to-debt ratio. SAB Biotherapeutics Inc (SABS) has a Cash Flow-to-Debt Ratio of -1.03x as of June 2026, meaning its operating cash flow of $-24.11 Million could theoretically repay -1% of its total liabilities ($23.43 Million) in one year. Check SAB Biotherapeutics Inc (SABS) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of SAB Biotherapeutics Inc (2019–2025)
Cash flow-to-debt ratio of SAB Biotherapeutics Inc from 2019 to 2025. Historical debt coverage capacity for SAB Biotherapeutics Inc across 7 annual periods. Check SABS cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
SAB Biotherapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
SAB Biotherapeutics Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for SAB Biotherapeutics Inc. For the full cash flow conversion analysis, see cash efficiency ratio of SAB Biotherapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.10x | $-44.78 Million | $21.32 Million | ▼ -11.6% |
| 2024 | -1.88x | $-34.29 Million | $18.23 Million | ▼ -99.6% |
| 2023 | -0.94x | $-25.12 Million | $26.64 Million | ▲ +20.2% |
| 2022 | -1.18x | $-23.46 Million | $19.85 Million | ▼ -2633.8% |
| 2021 | 0.05x | $1.99 Million | $42.59 Million | ▼ -91.8% |
| 2020 | 0.57x | $10.00 Million | $17.53 Million | ▲ +225.8% |
| 2019 | -0.45x | $-9.21 Million | $20.31 Million | — |